Flow cytometric immune monitoring of anti-CD19 CAR-T cells in an academic point-of-care program in Uruguay: implementation and operational assessment

Background Direct detection of circulating chimeric antigen receptor T (CAR-T) cells by flow cytometry provides information complementary to B-cell aplasia during immune monitoring after anti-CD19 CAR-T therapy. We describe the implementation and operational assessment of a multiparametric flow cytometry workflow for anti-CD19 CAR-T cell monitoring within an academic point-of-care cellular therapy program in Uruguay. Methods The assay was established for CAR-T product control and post-infusion monitoring. Technical implementation used an 8-color production panel and a locally adapted clinical monitoring panel on a 13-color DxFLEX cytometer. CAR detection used a biotinylated CD19 CAR Detection Reagent followed by PE-conjugated anti-biotin. Reagent titration, gating strategy, and an analytical sensitivity framework based on previously published criteria were assessed. B-cell aplasia was evaluated in a separate 10-color tube. Results The workflow was integrated into routine laboratory practice and applied during the initial clinical phase of the program. A working condition of 2 µL of CD19 CAR Detection Reagent and 2 µL of PE-conjugated anti-biotin were selected according to signal-to-noise performance and reagent use. For low-frequency interpretation, the analytical framework used a limit of blank of 8 events, a limit of detection of 13 events, and a lower limit of quantification of 22 events, adopted from published criteria rather than derived from a complete local recalculation. The method enabled direct CAR-T detection, assessment of B-cell aplasia, and characterization of CD4/CD8 distribution within the CAR-positive population. Conclusion Flow cytometry provided an integrated, locally available immune-monitoring strategy for an academic anti-CD19 CAR-T program, combining direct CAR-T detection with assessment of the B-cell compartment and T-cell phenotype. This operational experience may inform cellular therapy programs working under similar resource and implementation conditions.

Authors

Publication Details

Journal
Frontiers in Hematology
Published
2026-11-16
DOI
https://doi.org/10.3389/frhem.2026.2007169
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Flow cytometric immune monitoring of anti-CD19 CAR-T cells in an academic point-of-care program in Uruguay: implementation and operational assessment

Marcela Barrios, Lucía D’Andrea, Maria Ines Pereira, Luis Castillo et al.
1 links
Frontiers in Hematology
CAR-T cell therapy research
article

Flow cytometric immune monitoring of anti-CD19 CAR-T cells in an academic point-of-care program in Uruguay: implementation and operational assessment

Marcela Barrios, Lucía D’Andrea, Maria Ines Pereira, Luis Castillo, Vittoria Ceriani
article en

Abstract

Background Direct detection of circulating chimeric antigen receptor T (CAR-T) cells by flow cytometry provides information complementary to B-cell aplasia during immune monitoring after anti-CD19 CAR-T therapy. We describe the implementation and operational assessment of a multiparametric flow cytometry workflow for anti-CD19 CAR-T cell monitoring within an academic point-of-care cellular therapy program in Uruguay. Methods The assay was established for CAR-T product control and post-infusion monitoring. Technical implementation used an 8-color production panel and a locally adapted clinical monitoring panel on a 13-color DxFLEX cytometer. CAR detection used a biotinylated CD19 CAR Detection Reagent followed by PE-conjugated anti-biotin. Reagent titration, gating strategy, and an analytical sensitivity framework based on previously published criteria were assessed. B-cell aplasia was evaluated in a separate 10-color tube. Results The workflow was integrated into routine laboratory practice and applied during the initial clinical phase of the program. A working condition of 2 µL of CD19 CAR Detection Reagent and 2 µL of PE-conjugated anti-biotin were selected according to signal-to-noise performance and reagent use. For low-frequency interpretation, the analytical framework used a limit of blank of 8 events, a limit of detection of 13 events, and a lower limit of quantification of 22 events, adopted from published criteria rather than derived from a complete local recalculation. The method enabled direct CAR-T detection, assessment of B-cell aplasia, and characterization of CD4/CD8 distribution within the CAR-positive population. Conclusion Flow cytometry provided an integrated, locally available immune-monitoring strategy for an academic anti-CD19 CAR-T program, combining direct CAR-T detection with assessment of the B-cell compartment and T-cell phenotype. This operational experience may inform cellular therapy programs working under similar resource and implementation conditions.

Frontiers in HematologyVol. 5
Good health and well-being
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon